{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Sabrina", "organization": "", "rank": 1, "lastname": "TAVERNISE"}], "original": "By SABRINA TAVERNISE"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Food and Drug Administration approves eteplirsen, medication for Duchenne muscular dystrophy, overriding objections by their own experts and bowing to intense patient lobbying; vote leads stock of drug maker Sarepta Therapeutics to soar. ", "multimedia": [{"type": "image", "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "legacy": {"wide": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "F.D.A. Clears Debated Drug That Patients Lobbied For", "main": "F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For"}, "print_page": "1", "keywords": [{"value": "Muscular Dystrophy", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Sarepta Therapeutics Inc.", "is_major": "Y", "rank": "3", "name": "organizations"}, {"value": "Clinical Trials", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "5", "name": "subject"}], "snippet": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness....", "source": "The New York Times", "lead_paragraph": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness.", "word_count": "747", "pub_date": "2016-09-20T04:00:00+0000", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html", "_id": "57e05a7b95d0e021d7987280"}